<DOC>
	<DOC>NCT01213485</DOC>
	<brief_summary>This observational study will evaluate the course of treatment, the efficacy on anemia and the safety of Mircera (methoxy polyethylene glycol-epoetin beta) in patients with chronic kidney disease on dialysis. Eligible patients will be on either haemodialysis or peritoneal dialysis and treatment-naïve for or having had prior therapy with erythropoiesis stimulating agents (ESA). Data will be collected from each patient for 12 months.</brief_summary>
	<brief_title>An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease on Dialysis (HORTENSIA)</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Chronic kidney disease, on dialysis for &gt; 3 months Treatmentnaïve or previous treatment with ESA Initiation of treatment with Mircera for renal insufficiency associated anemia by decision of the treating physician Participation in a clinical trial Anemia due to an associated malignant pathology</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>